Biocept Stock

Biocept Gross Profit

Delisted

The Gross Profit of Biocept (BIOC) as of Aug 18, 2026 is -2.58 M USD. In the previous year, Gross Profit was 23.49 M USD — a change of -110.99% (lower).

Gross Profit

-2.58 MUSD

YoY

-110.99%

Last updated:

Gross Profit of Biocept is 2026 -2.58 M USD. Gross Profit of Biocept was 2025 23.49 M USD. It decreases by -110.99% lower compared to the previous year.

The Biocept Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2019
-98.56 base
Jan 1, 2020
22.30 base
Jan 1, 2021
38.34 base
Jan 1, 2022
-9.99 base
Jan 1, 2023 (e)
-104.11 base
Jan 1, 2024 (e)
-39.91 base
Jan 1, 2025 (e)
-12.02 base
Jan 1, 2026 (e)
-11.94 base
YEARGROSS MARGIN (%)
2026 est -11.94
2025 est -12.02
2024 est -39.91
2023 est -104.11
2022 -9.99
2021 38.34
2020 22.30
2019 -98.56
2018 -209.26
2017 -84.37
2016 -114.70
2015 -653.58
2014 -1,526.91
2013 -1,635.56
2012 -999.56
2011 -1,546.58
Access this data via the Eulerpool API

Biocept Revenue

Biocept Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
5.53 M USD
-23.06 M USD
-24.61 M USD
Jan 1, 2020
27.46 M USD
-15.47 M USD
-17.04 M USD
Jan 1, 2021
61.25 M USD
-2.41 M USD
-2.82 M USD
Jan 1, 2022
25.86 M USD
-31.98 M USD
-32.09 M USD
Jan 1, 2023 (e)
2.48 M USD
-24.44 M USD
-98.66 M USD
Jan 1, 2024 (e)
6.47 M USD
-23.53 M USD
-24.53 M USD
Jan 1, 2025 (e)
21.48 M USD
-15.82 M USD
-15.11 M USD
Jan 1, 2026 (e)
21.63 M USD
-3.19 M USD
-8.45 M USD

Biocept Margins

Biocept stock margins

The Biocept margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biocept. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biocept.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
-98.56 %
-417.05 %
-445.23 %
Jan 1, 2020
22.30 %
-56.33 %
-62.06 %
Jan 1, 2021
38.34 %
-3.93 %
-4.61 %
Jan 1, 2022
-9.99 %
-123.69 %
-124.09 %
Jan 1, 2023 (e)
-9.99 %
-985.41 %
-3,978.37 %
Jan 1, 2024 (e)
-9.99 %
-363.61 %
-379.17 %
Jan 1, 2025 (e)
-9.99 %
-73.64 %
-70.36 %
Jan 1, 2026 (e)
-9.99 %
-14.74 %
-39.08 %

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Gross Profit of Biocept is -2.58 M USD in 2026.

Gross Profit of Biocept changed from 23.49 M USD to -2.58 M USD, representing a -110.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Biocept since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Biocept historically and in real time.

Access this data via the Eulerpool API

Income Statement — Biocept

All Key Metrics — Biocept